Finanzen von Voyager Therapeutics Inc (VYGR)VYGRVoyager Therapeutics Inc

Evaluating the bottom line, Voyager Therapeutics, Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -833.87%, while the net margin is -773.24%. These profitability ratios, combined with a Return on Equity (ROE) of -54.09%, provide a clear picture of how effectively VYGR converts its operational activities into shareholder value.

In the context of the broader market, VYGR competes directly with industry leaders such as DTIL and PEPG. With a market capitalization of $201.49M, it holds a significant position in the sector. When comparing efficiency, VYGR's gross margin of 100.00% stands against DTIL's 100.00% and PEPG's N/A. Such benchmarking helps identify whether Voyager Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Voyager Therapeutics has shown fluctuating revenue, with Q1 2026 revenue at $2.6 million but a net loss of $27.9 million. The gross margin remains strong at 100%, but the company is facing challenges in profitability.